Targeting a novel apoptotic pathway in human disease.
IGFBP3
TMEM219
apoptosis
intestinal stem cells
pancreatic beta cells
Journal
BioEssays : news and reviews in molecular, cellular and developmental biology
ISSN: 1521-1878
Titre abrégé: Bioessays
Pays: United States
ID NLM: 8510851
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
09
03
2023
received:
30
11
2022
accepted:
15
03
2023
medline:
17
5
2023
pubmed:
31
3
2023
entrez:
30
3
2023
Statut:
ppublish
Résumé
Apoptotic pathways have always been regarded as a key-player in preserving tissue and organ homeostasis. Excessive activation or resistance to activation of cell death signaling may indeed be responsible for several mechanisms of disease, including malignancy and chronic degenerative diseases. Therefore, targeting apoptotic factors gained more and more attention in the scientific community and novel strategies emerged aimed at selectively blocking or stimulating cell death signaling. This is also the case for the TMEM219 death receptor, which is activated by a circulating ligand, the Insulin-like growth factor binding protein 3 (IGFBP3) and induces a caspase-8-dependent apoptosis of the target cells. Interestingly, stimulation of the IGFBP3/TMEM219 axis exerts an anti-proliferative effect, while blockade of the TMEM219 deleterious signal protects TMEM219-expressing cells of the endocrine pancreas, lung, and intestine from damage and death. Here, we summarize the most updated reports on the role of the IGFBP3/TMEM219 apoptotic axis in disease conditions, including intestinal disorders and diabetes, and we describe the advancements in designing and testing novel TMEM219-based targeting approaches in emerging potential clinical applications.
Identifiants
pubmed: 36998110
doi: 10.1002/bies.202200231
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200231Informations de copyright
© 2023 The Authors. BioEssays published by Wiley Periodicals LLC.
Références
Christgen, S., Tweedell, R. E., & Kanneganti, T. D. (2022). Programming inflammatory cell death for therapy. Pharmacology & Therapeutics, 232, 108010.
Petrazzuolo, A., Perez-Lanzon, M., Martins, I., Liu, P., Kepp, O., Minard-Colin, V., Maiuri, M. C., & Kroemer, G. (2021). Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death & Disease, 12(8), 713.
Ingermann, A. R., Yang, Y. F., Han, J., Mikami, A., Garza, A. E., Mohanraj, L., Fan, L., Idowu, M., Ware, J. L., Kim, H. S., Lee, D. Y., & Oh, Y. (2010). Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. Journal of Biological Chemistry, 285(39), 30233-30246.
Baxter, R. C. (2001). Signalling pathways involved in antiproliferative effects of IGFBP-3: A review. Molecular Pathology, 54(3), 145-148.
Oh, Y., Gucev, Z., Ng, L., Muller, H. L., & Rosenfeld, R. G. (1995). Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Progress in Growth Factor Research, 6(2-4), 503-512.
Cai, Q., Dozmorov, M., & Oh, Y. (2020). IGFBP-3/IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in Cancer Cells, 9(5), 1261.
Gheysarzadeh, A., Bakhtiari, H., Ansari, A., Emami Razavi, A., Emami, M. H., & Mofid, M. R. (2019). The insulin-like growth factor binding protein-3 and its death receptor in pancreatic ductal adenocarcinoma poor prognosis. Journal of Cellular Physiology, 234(12), 23537-23546.
Joyce, S., & Nour, A. M. (2019). Blocking transmembrane219 protein signaling inhibits autophagy and restores normal cell death. PLoS ONE, 14(6), e0218091.
Lee, C. M., He, C. H., Nour, A. M., Zhou, Y., Ma, B., Park, J. W., Kim, K. H., Dela Cruz, C., Sharma, L., Nasr, M. L., Modis, Y., Lee, C. G., & Elias, J. A. (2016). IL-13Ralpha2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nature Communications, 7, 12752.
Kanth, P., & Inadomi, J. M. (2021). Screening and prevention of colorectal cancer. British Medical Journal, 374, n1855.
Aziz, I., & Simren, M. (2021). The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol, 6(2), 139-148.
D'Addio, F., & Fiorina, P. (2016). Type 1 diabetes and dysfunctional intestinal homeostasis. Trends in Endocrinology and Metabolism, 27(7), 493-503.
D'Addio, F., La Rosa, S., Maestroni, A., Jung, P., Orsenigo, E., Ben Nasr, M., Tezza, S., Bassi, R., Finzi, G., Marando, A., Vergani, A., Frego, R., Albarello, L., Andolfo, A., Manuguerra, R., Viale, E., Staudacher, C., Corradi, D., Batlle, E., … Fiorina, P. (2015). Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy. Cell Stem Cell, 17(4), 486-498.
D'Addio, F., Maestroni, A., Assi, E., Ben Nasr, M., Amabile, G., Usuelli, V., Loretelli, C., Bertuzzi, F., Antonioli, B., Cardarelli, F., El Essawy, B., Solini, A., Gerling, I. C., Bianchi, C., Becchi, G., Mazzucchelli, S., Corradi, D., Fadini, G. P., Foschi, D., … Fiorina, P. (2022). The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. Nature Communications, 13(1), 684.